FOR COMPANIES & DEAL TEAMS

A Deal-Ready Data Room, in Minutes.

Raising a round or preparing for a sale — Marveri builds and organizes your data room, accelerates diligence, flags risks before the other side finds them, and impresses every investor or acquirer with your corporate house in order.

Book a Demo

Automatically organize and build your data room.

Connect your Google Drive, SharePoint, or drag files in directly. Marveri renames every document, sorts them into a clean data room structure, detects duplicates, and flags anything missing or incomplete. Your data room is ready to impress investors or buyers in minutes.

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (1).pdf
Organizational Documents
8
Audited Financials 2023 2024 FINAL.pdf
Formation Documents
3
employment agreement - morrison (executed copy).pdf
Certus, Inc. - Amended and Restated Certificate of Incorporation - August 30, 2023.pdf
Lease Agreement 200 Congress Austin TX.pdf
Certus, Inc. - Amended and Restated Bylaws - March 15, 2024.pdf
CUSTOMER_LIST_CONFIDENTIAL.xlsx
Certus, Inc. - Certificate of Good Standing (Delaware) - January 10, 2026.pdf
Meridian_Health_MSA_2022_executed (signed by both parties).pdf
Board and Stockholder Consents
5
D&O policy renewal cert 2024.pdf
Material Contracts
12
Board consent re option grants 9-15-23.pdf
Certus, Inc. - Master Services Agreement (Meridian Health Systems) - June 15, 2022.pdf
IP Assignment - Chen.pdf
Certus, Inc. - Distribution Agreement (Whitfield & Partners LLP) - August 15, 2023.pdf
Non-Compete (Morrison) final executed.pdf
Employment
11
Wells Fargo Credit Agreement (revolving).pdf
Executive Employment Agreements
4
federal and state tax returns.zip
Certus, Inc. - Employment Agreement (James Morrison, CEO) - March 1, 2021.pdf
Stock Option Plan 2020 as amended.pdf
Certus, Inc. - Non-Competition Agreement (James Morrison) - March 1, 2021.pdf
DISTRIBUTOR AGREEMENT (signed).pdf
Financial Statements
6
Environmental Phase I - 200 Congress Ave (2019).pdf
Certus, Inc. - Audited Financial Statements (FY2024) - March 28, 2025.pdf
pending_litigation_summary.pdf
Insurance
6
Workers Comp Insurance Certificate.pdf
Certus, Inc. - Directors and Officers Liability Policy - February 1, 2024.pdf

Respond to request lists on day one.

Marveri automatically responds to every request based on your entire document repository and organizes all of your documents to structure your data room exactly how the other side requested.

Certus, Inc. — Due Diligence Request List.xlsx
DUE DILIGENCE REQUEST LIST
Date: April 2, 2026 · Project Redwood · Generated by Marveri
ID
Category
Request
Response
Status
Responsive Docs
Internal Notes
10
A.7
Officers & Directors
List of current officers, directors, and key employees.
• J. Chen (CEO, Director)
• S. Connolly (President, Secretary)
• D. Mishkin (CFO, Treasurer)
• M. Torres (Independent Director)
Provided
Board Consent (appt).pdf ↗
Indemnification Agmts.zip ↗
Org Chart (2026).pdf ↗
Torres appointed per Series B term sheet. Board observer: Redpoint per IRA §3.1.
11
A.8
Subsidiaries
List of all subsidiaries, joint ventures, and foreign qualifications.
Certus UK Ltd. (wholly owned). Certus Solutions LLC (wholly owned). No joint ventures. Foreign qualified in CA, NY, TX.
Provided
UK Certificate of Inc.pdf ↗
LLC Op. Agreement.pdf ↗
Foreign Qual. Certs.zip ↗
UK sub formed for EU customer contracts. TX qualification lapsed Dec 2025 — reinstatement pending.
12
B
Capitalization and Securities Matters
13
B.1
Capitalization
Fully-diluted cap table including options, warrants, convertibles, SAFEs.
See attached. Common: 28.4M shares. Preferred: Series A (4.2M), A-1 (2.1M), B (8.6M). Options: 3.8M. Warrants: 1.2M.
In Progress
Cap Table (Mar 2026).xlsx ↗
Warrant Ledger.xlsx ↗
Warrant Calculation DiscrepancyWarrant ledger shows 1.2M; Series B SPA side letter references 1.45M. 250K shares unreconciled.
14
B.2
Equity Documents
All agreements relating to issuances of equity, options, and warrants.
See documents in folder B.2.
Provided
SPA (Series B).pdf ↗
SPA (Series A).pdf ↗
RSPA (Connolly).pdf ↗
RSPA (Mishkin).pdf ↗
+ 62 more
409A Valuation StaleMost recent 409A dated Sept 2024 (18 mos). Post-Jan 2025 grants lack safe harbor.
15
B.3
SAFEs & Notes
SAFEs, convertible notes, and all convertible instruments.
See responsive documents in folder B.3.
In Progress
SAFE (YC).pdf ↗
SAFE (Angel Synd.).pdf ↗
Conv. Note (2020).pdf ↗
+ 2 more
MFN Clause Triggered2018 SAFE ($6M cap) includes MFN. Subsequent SAFE at $4.5M cap — earlier holders may claim lower cap.
16
B.4
Equity Incentives
Equity incentive plans and all option/RSU grant agreements.
See documents in folder B.4.
Provided
2019 Equity Plan.pdf ↗
Grant Agreements.zip ↗
Board Consent (Plan).pdf ↗
+ 44 more
Single-Trigger Acceleration8 executive grants include single-trigger acceleration on CoC. Aggregate: 1.4M shares.
20
C
Material Contracts

Know what a buyer will find — before they find it.

Marveri analyzes every document in your repository to find the key issues that a buyer or investor will flag — corporate governance, capitalization, material contracts, IP, employment, and more. See the critical issues you need to address before diligence starts, not after the other side raises them. Give your deal lawyer a targeted list of critical items to start addressing.

Due Diligence Report
Synthetica AI, Inc. — Project Alpine
Prepared by Marveri
Date March 28, 2026
Executive Summary

Synthetica AI, Inc. is a Delaware corporation operating a cloud-hosted enterprise AI platform [9], currently party to a merger agreement with Apex Software Corporation [10] (closing targeted by June 30, 2026). This report reviews corporate formation and governance documents [25], capitalization records [27], financing documents [26], material contracts, intellectual property filings [21], litigation records [20], insurance policies [1], [2], [3], employment records [28], tax filings [33], and audited financial statements [6].

The following findings define the company’s current legal posture:

  • Unresolvable capitalization uncertainty. Series A preferred shares appear as 0 [6], 4.5 million [8], or 15 million [7] outstanding across four sources, directly affecting every approval threshold for the merger.
  • Critical documentation gaps. Bylaws, all Stock Purchase Agreements, the equity incentive plan, the stock ledger, the credit agreement, and stockholder consents for the February 2025 Series C financing [26] are among dozens of material documents not produced.
  • Expired and at-risk contracts. The AWS enterprise agreement [17] expired December 2025. The JPMorgan Chase technology MSA [13] expired approximately February 2026. Three insurance policies expired February 15, 2026 with no evidence of renewal.
  • Change-of-control consents. Four agreements require consent or notice for the merger [7]; none has been obtained [10].
  • IP ownership gaps and active patent litigation. Two patents were filed before or days after incorporation without documented assignment [21], and NeuralPath Technologies has filed a patent suit in D. Del. [20] asserting a patent bearing the same number the company claims as its own.
  • R&D tax credit discrepancies. The $4.8M credit on the filed return [33] is nearly double the $2.5M produced by the supporting Deloitte study [34].
Company Timeline

The following table reconstructs key corporate, financing, and operational events. Events in bold present open diligence issues.

DateEventSource
Jan. 15, 2020Incorporation (Delaware); Certificate of Incorporation filed[25]
Jan. 2020Marchetti employment agreement references option grant — no 409A valuation exists[23]
Mar. 15, 20202020 Equity Incentive Plan adopted (not produced)[27]
Feb. 15, 2021Stanford exclusive license executed (10-year term)[19]
Nov. 2021Series A financing — 15M shares at $1.60/share ($24M); Sequoia Capital lead[7]
Mar. 31, 2022First documented 409A valuation — $0.52/share[27]
Mar. 1, 2023JPMorgan Chase Technology MSA executed ($2.4M/yr)[13]
Jun. 2023Series B financing — 10M shares at $5.50/share ($55M); a16z lead[7]
Jan. 1, 2023AWS Enterprise Agreement executed ($3.6M committed)[17]
Dec. 31, 2025AWS Enterprise Agreement expired — no renewal documented[17]
Feb. 2025Series C financing — 7.5M shares at $12.00/share ($90M); Tiger Global lead[7]
Feb. 15, 2026D&O, CGL, and Cyber insurance policies all expired[1][2][3]
Feb. 15, 2026Board unanimously approves merger agreement with Apex Software Corp.[10]
Feb. 28, 2026JPMorgan Chase MSA expired — no renewal documented[13]
Jun. 30, 2026Merger closing deadline (reverse triangular; Synthetica survives as Apex subsidiary)[10]

Dates reconstructed from [6], [7], [8], [10], [13], [17], [19], [23], [25], [27]

The cadence of issuances and the overlap between the August 2022 SAFE conversion mechanics [22] and the Series B pricing resolution [24] remain the most scrutinized sequence in the working group’s request list. The 409A re-valuation initiated in April 2025 [15] overlaps the November 2025 option grants at a $14.20 strike price [18], and no board consent has been produced reconciling the two valuations. The merger timeline further compresses the diligence window: closing is targeted for June 30, 2026, roughly five months from the signing date, with interim operating covenants and regulatory filings to complete.

Two material renewal items fall inside the diligence period and have no corresponding action item in the data room — the AWS Enterprise Agreement (expired December 2025) [17] and the JPMorgan Chase Technology MSA (expired February 2026) [13]. The board minutes from the February 15, 2026 meeting [10] reference neither renewal nor alternative supplier negotiations, a gap counsel should surface with management before signing.

Corporate Structure and Governance
Entity Status and Organizational Documents

Good standing. A Good Standing Certificate dated January 31, 2026 confirms good standing in Delaware with all franchise taxes current. [35] The company is qualified as a foreign corporation in California, New York, Texas, Washington, Massachusetts, Colorado, and Illinois. [7]

Delaware file number discrepancy. The Good Standing Certificate references File No. 4524987 [35], while the Disclosure Schedules and CEO Certificate both reference File No. 5412891. [7], [8]

Probable UK subsidiary. The audited financials are styled as “Consolidated” and disclose a London lease [6]. No subsidiary formation documents, intercompany agreements, or entity details appear in the reviewed documents.

Charter Provisions
Class / SeriesAuthorizedPar ValueIssuance PriceAnti-Dilution
Common Stock140,000,000$0.0001
Series A Preferred15,000,000$0.0001$1.60Broad-based WA
Series B Preferred10,000,000$0.0001$5.50WA + Full Ratchet
Series C Preferred7,500,000$0.0001$12.00Broad-based WA
Undesignated Preferred27,500,000$0.0001
Total200,000,000

Source: [25 (A&R Certificate of Incorporation)]

Anti-dilution conflict. The charter [25] provides broad-based weighted average anti-dilution for Series A and B, but Series B additionally carries full ratchet protection for down-rounds below $5.50/share. The IRA [26] describes only broad-based weighted average for all series. Under Delaware law, the charter controls.

Subsidiaries & Intercompany Agreements

The audited financials [6] disclose a London office lease assumed at the consolidated level, implying an active UK subsidiary. ETTL UK Ltd. was formed in November 2024 [6], yet no subsidiary formation documents, intercompany services agreement, or transfer-pricing memorandum have been produced in the data room [7]. The missing intercompany agreement is material for purposes of Section 482 compliance and for the pre-closing restructuring deliverable.

Board Composition & Governance

The bylaws [25] authorize a five-seat board composed of three investor-designated directors (Sequoia, Andreessen Horowitz, Tiger Global), the Chief Executive Officer, and one independent director. The independent seat has been vacant since July 2025 following the resignation of Michelle Park [8]; no replacement has been appointed. Section 4.4 of the Stockholders’ Agreement [27] requires the independent director to sit on the audit and compensation committees — both currently operating with three members in violation of the agreement.

Capitalization
RoundDateShares IssuedPrice/ShareGross ProceedsLead Investor
Series ANov. 202115,000,000$1.60$24,000,000Sequoia Capital
Series BJun. 202310,000,000$5.50$55,000,000Andreessen Horowitz
Series CFeb. 20257,500,000$12.00$90,000,000Tiger Global
Total Preferred Raised$169,000,000

Sources: [7], [27], [6]

Preferred Stock: material inconsistency. Three mutually inconsistent positions exist. The equity statement [6] shows zero preferred shares at the January 1, 2024 opening balance. Yet the funding history in the Disclosure Schedules [7] confirms 15,000,000 Series A shares were issued in November 2021.

SourceSeries ASeries BSeries CTotal PreferredMajority Threshold
Audited Financials [6]010,000,0007,500,00017,500,0008,750,001
CEO Certificate [8]4,500,00010,000,0007,500,00022,000,00011,000,001
Disc. Sched. / Cap Table [7], [27]15,000,00010,000,0007,500,00032,500,00016,250,001

Discrepant figures shown in bold. Majority threshold per Section 4.5 of [25].

Option Pool & 409A Valuation

The board-approved equity incentive plan [8] authorizes an option pool of 5,200,000 shares, of which 3,837,500 are issued and outstanding across 47 grant agreements. Weighted-average strike price is $4.12. The most recent 409A valuation [15], dated October 2025, sets fair market value at $11.40 per share — approximately 5% below the Series C price. Three option grants issued in November 2025 reference a $14.20 strike [18], indicating a board re-valuation not reflected in the 409A report on file.

Convertible Instruments Outstanding

The data room contains four SAFEs executed during the Series B interim period (September 2022 to April 2023), aggregate purchase price of $8,500,000 [22]. Three use the standard post-money valuation cap format; one (executed with Founders Circle) includes a full-ratchet anti-dilution provision inconsistent with the other three [24]. All four convert automatically upon the next Qualified Financing at the lower of the valuation cap or the Series D price, creating a material dilution overhang upon any future financing event.

Material Contracts
CounterpartyTypeAnnual ValueTermCoC ConsentStatus
JPMorgan ChaseTechnology MSA$2,400,0003/1/23–2/28/26YesExpired
Amazon Web ServicesEnterprise EA$1,200,0001/1/23–12/31/25YesExpired
Stanford UniversityExclusive License~$768,0002/15/21–2/15/31YesActive
Silicon Valley BankCredit Facility$20,000,000Not producedYesUnknown
Tishman SpeyerOffice Lease (SF HQ)$1,080,0003/1/22–2/28/27YesActive
Deloitte & ToucheAudit Engagement$385,000Annual renewalNoActive
SalesforceCRM Subscription$192,0007/1/24–6/30/27NoActive

Sources: [13], [17], [19], [7], [30], [6], [11], [12], [14]

Insurance covenant noncompliance. The JPMorgan MSA [13] requires $10M cyber liability, $5M CGL per occurrence, $5M E&O, and $5M D&O. Current cyber coverage is $5M [3] and CGL is $1M per occurrence / $2M aggregate [2], both below contractual requirements.

Credit agreement not produced. The Disclosure Schedules [7] reference a $20M revolving credit facility with Silicon Valley Bank. The credit agreement itself, any amendments, compliance certificates, and current draw amounts were not included in the data room [30].

Customer Concentration

Based on the FY2025 revenue schedule [6], top-three enterprise customers account for 54% of ARR. The largest customer — a Fortune 500 financial services firm [16] — represents 28% of ARR under a three-year MSA [16] expiring June 2026. The MSA contains a 90-day termination-for-convenience clause available to the counterparty, and no renewal has been documented [7].

Indemnification & Liability Caps

Standard indemnification caps across enterprise agreements range from 1× to 3× trailing-twelve-month fees, except the Stanford University Exclusive License [11] which carries uncapped indemnification for third-party IP claims. Data Processing Agreements [14] with JPMorgan, Amazon, and three other enterprise customers include unlimited liability carve-outs for data-breach events — a deviation from the company's template MSA terms.

Understand all of your obligations at a glance.

See change-of-control clauses, exclusivity restrictions, termination triggers, and more across every agreement at once. Know what’s in your contracts before a buyer does — and address anything that could slow down or complicate your deal.

File Name Change of Control Exclusivity Non-Solicit MFN Non-Compete Governing Law
Ridgewood Capital MSA.pdf
×
<
14
/ 42
>
Page Width
+
Master Services Agreement · Execution Version Confidential
Article 14. Miscellaneous
14.1 Compliance with Laws. Each party shall comply with all applicable federal, state, and local laws, rules, and regulations in the performance of its obligations under this Agreement.
14.2 Dispute Resolution. Any controversy or claim arising out of or relating to this Agreement shall be finally resolved by binding arbitration administered by JAMS before a single arbitrator seated in New York, New York.
14.3 Assignment; Change of Control. Neither party may assign or transfer this Agreement or any of its rights or obligations hereunder, whether by operation of law or otherwise, without the prior written consent of the other party. For purposes of this Section 14.3, any merger, consolidation, reorganization, sale of all or substantially all of the assets of a party, or other transaction resulting in a Change of Control of such party shall be deemed an assignment requiring the other party’s prior written consent.
Any purported assignment in violation of this Section 14.3 shall be null and void ab initio. Subject to the foregoing, this Agreement shall bind and inure to the benefit of the parties and their respective successors and permitted assigns.
— 14 —

Accelerate your deal’s biggest bottleneck — disclosure schedules.

Upload your purchase agreement and Marveri automatically drafts your full disclosure schedules, cross-referenced against your entire document set. Hand your lawyers a complete first draft. They refine and finalize, cutting weeks off the timeline and thousands of dollars in expenses.

Schedule 3.7
Material Contracts
(a) Contracts Requiring Consent to Assignment or Containing Change-of-Control Provisions.
1. Master Services Agreement, dated January 15, 2022, between Meridian Health Systems, Inc. and the Company (consent to assign; CoC termination right). [7.01]
2. Enterprise License Agreement, dated September 1, 2023, between Apex Financial Corp. and the Company (automatic termination upon CoC). [7.04]
3. Data Processing Agreement, dated March 22, 2023, between NovaTech Solutions GmbH and the Company (consent to assign, not to be unreasonably withheld). [7.09]
[Internal Note: The Apex ELA (item 2) provides for automatic termination upon change of control with no cure period. Buyer counsel should obtain waiver prior to closing.]
(b) Contracts Involving Annual Payments in Excess of $250,000.
1. The contracts listed in Section (a)(1) through (a)(3) above.
2. SaaS Subscription Agreement, dated June 1, 2022, between Caldwell Group, LLC and the Company. [7.12]
3. Platform License Agreement, dated February 28, 2024, between Commonwealth Bancshares and the Company. [7.18]
4. Reseller Agreement, dated August 15, 2023, between Whitfield & Partners LLP and the Company. [7.22]
(c) Non-Competition and Non-Solicitation Agreements.
1. Non-Competition Agreement, dated March 1, 2021, between the Company and David R. Harmon (CEO). [7.30]
2. Restrictive Covenant Agreement, dated June 15, 2022, between the Company and Sarah K. Whitmore (CTO). [7.31]
3. Non-Solicitation Agreement, dated January 10, 2023, between the Company and James L. Osbourne (VP, Sales). [7.32]
[Internal Note: Enforceability of the Harmon non-compete (24 months) under Cal. Bus. & Prof. Code § 16600 should be evaluated by Buyer.]
(d) Guarantees and Letters of Credit.
1. Irrevocable Standby Letter of Credit No. LC-2023-0491, issued by Silicon Valley Bank, N.A., dated April 5, 2023 ($500,000). [7.40]
2. Personal Guaranty, dated March 1, 2021, by David R. Harmon in favor of First Republic Bank, N.A., re: Revolving Credit Facility ($3,000,000). [7.41]

Even More Tools to Accelerate Your Transaction

Compare across every term sheet.

Compare term sheets, side letters, or SAFEs across investors — see every term change at a glance before you sign.

Ask any question. Get a cited report.

Query across your entire document repository. "Which contracts have change-of-control provisions?" Every answer is cited to the source.

Automatic OCRDocument summariesDuplicate detectionMissing signature detectionCap table tie-outSAFE comparisonIP assignment check83(b) election trackingOne-click index downloadCross-document referencesChange of control provisionsAnti-assignment analysisExclusivity clause searchTermination trigger detectionNon-compete analysisMFN provision detectionGoverning law extractionExport to Word with citationsExport to Excel with citationsDisclosure schedule draftingPersonnel & compensation censusCorporate structure mappingExact quote verificationVerified math calculationsDocument status trackingName history trackingData-room version historyGoogle Drive integrationSharePoint / OneDrive syncDropbox integrationRole-based access controlSOC 2 Type II certified
SOC 2 Type II compliance badge

Security Designed for the Most Confidential Data

Encryption of all data in transit and at rest.
SOC 2 Type II.
Zero training.

What our Customers are Saying:

"I remain blown away by the product."
- Corporate Partner
“Marveri is the single greatest product I’ve ever used.”
- Founding Corporate Partner
"Dream come true."
- Junior Associate
"I’m sold. Going to start requiring anyone working on my clients to use Marveri."
- Founding Senior Attorney
"I literally love Marveri and can’t imagine not having it."
- Junior Associate
"I remain blown away by the product."
- Corporate Partner
“Marveri is the single greatest product I’ve ever used.”
- Founding Corporate Partner
"Dream come true."
- Junior Associate
"I’m sold. Going to start requiring anyone working on my clients to use Marveri."
- Founding Senior Attorney
"I literally love Marveri and can’t imagine not having it."
- Junior Associate
“Your product is criminally cheap.”
- Head of Small Law Firm
“Finally found the perfect tool.”
- Senior M&A attorney
“I’m only a week in and already getting 10x the value.”
- Senior Fund Lawyer
"Your product is amazing."
- Corporate Partner
“Your product is criminally cheap.”
- Head of Small Law Firm
“Finally found the perfect tool.”
- Senior M&A attorney
“I’m only a week in and already getting 10x the value.”
- Senior Fund Lawyer
"Your product is amazing."
- Corporate Partner
Close

See for yourself.

Close

Success

Your submission has been received.
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.